Verastem Oncology To Present Updated Clinical Data From Phase 1/2 TARGET-D-101 Study Of VS-7375 In Previously Treated Patients With KRAS G12D-Mutated Metastatic NSCLC, At IASLC/ASCO 2026 NACLC26
Benzinga Newsdesk 2 days ago
News
Updated Phase 1/2 TARGET-D 101 data for KRAS G12D-mutated metastatic NSCLC to be presented on December 5, 2026, during Oral Abstract Session 1Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to
Updated Phase 1/2 TARGET-D 101 data for KRAS G12D-mutated metastatic NSCLC to be presented on December 5, 2026, during Oral Abstract Session 1
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) has been selected for oral presentation at the IASLC/ASCO 2026 North America Conference on Lung Cancer (NACLC26), taking place December 4–6, 2026. A trial in progress (TiP) abstract on the Phase 2 TARGET-D 202 registration-directed NSCLC trial has also been accepted for poster presentation.
